Five-fold increased risk of relapse following breaks in antipsychotic treatment of first episode psychosis.

BACKGROUND: A key problem in the management of first episode psychosis is that patients are often reluctant to take antipsychotic medication, especially once their presenting symptoms have resolved. Clinicians may be tempted to trial a 'break in treatment' in such patients. AIM: To assess the impact of interruptions in the antipsychotic treatment of first episode psychosis. METHOD: Treatment adherence and clinical course were assessed during the 18months following presentation in 136 consecutive patients with a first episode of psychosis in 2003-2005 by a systematic retrospective casenote review. Regression analyses were used to examine the time to remission and the risk of relapse in patients who had stopped antipsychotics for one month or more. RESULTS: There were breaks in antipsychotic treatment of ≥1month in more than half of the patients (n=73; 58%). When these occurred before they had recovered (n=22; 17%), the time to remission was almost twice as long as in patients in whom treatment was continuous (t=2.9, P=0.01). Patients in whom treatment was interrupted were 5 times more likely to have relapsed than those in whom it was continuous (p=0.0001, 95%CI 2.1-11). The mean time to relapse following an interruption in treatment was 3months. CONCLUSION: If the treatment of first episode psychosis with antipsychotic medication is stopped for a month or more, remission may be delayed and the risk of relapse following remission may be substantially increased.

Management of medically unexplained symptoms: outcomes of a specialist liaison clinic.

Aims and method Service utilisation and clinical outcomes of a newly developed specialist primary-secondary care liaison clinic for patients with medically unexplained symptoms (MUS) were evaluated in a cross-sectional and feasibility pilot study. The impact of body-oriented psychological therapy (BOPT) was explored in a small cohort of patients with an identified somatoform disorder. Results Of 147 consecutive referrals, 113 patients engaged with the assessment process. Of patients with MUS, 42% (n = 45) had a primary diagnosis of somatoform disorder, 36% (n = 38) depressive disorder, and depressive symptoms (even subsyndromal) mediated the effect of somatic symptoms. A marked variation of presenting complaints and service utilisation across ethnic groups was noted. A significant reduction in somatic symptom levels and service utilisation was achieved for patients undergoing BOPT. Clinical implications A high proportion of patients with MUS have undiagnosed and therefore untreated mental disorders. New and locally derived collaborative care models of active engagement in primary care settings are required. Patients with somatoform disorder may benefit from BOPT; this requires further evaluation in adequately powered clinical trials.

Esquire trial: efficacy and adverse effects of quetiapine versus risperidone in first-episode schizophrenia.

OBJECTIVE: To compare the efficacy and adverse effect profiles of 2 widely used atypical antipsychotics in the short-term phase of first-episode schizophrenia in patients who were treatment-naive. A secondary objective was to establish the effective dose of these drugs in this context. METHODS: A total of 72 patients with a first episode of schizophreniform psychosis (schizophrenia spectrum disorder) with less than 2 weeks of exposure to antipsychotic medication were randomized to quetiapine or risperidone in a single-blind 12-week controlled trial. Psychopathologic diagnoses and adverse effects were assessed by blinded raters at 4 weekly intervals. Medication was administered by a specialized clinical team following dosing guidelines. Data were analyzed using an intention-to-treat paradigm. RESULTS: Both quetiapine and risperidone were associated with a reduction in immediate symptoms and relatively few adverse effects other than weight gain. There was no statistically significant difference between the 2 compounds in adverse effects, relative efficacies, or adherence to treatment. The median (SD) time to cessation for patients randomized to quetiapine was 65.3 (41.85) days and that for risperidone was 82.5 (44.88) days. There was no statistically significant difference between time to discontinuation for the 2 compounds. The mean daily doses prescribed were 375 mg of quetiapine and 2.72 mg of risperidone. CONCLUSIONS: Quetiapine and risperidone are both effective treatments in first-episode schizophrenia at doses lower than those used in patients with long-term schizophrenia and are similar in efficacy and the incidence of adverse effects.